Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Black Diamond Therapeutics, Inc.BDTX · Entity 6669 | Director | June 26, 2026 | June 29, 2026 |
| CRISPR Therapeutics AGCRSP · Entity 3852 | Director · Chief Executive Officer | October 13, 2026 | October 15, 2026 |
| Oruka Therapeutics, Inc.ORKA · Entity 3781 | Director | June 02, 2026 | June 03, 2026 |
| Repare Therapeutics Inc.RPTX · Entity 68433 | Director | June 17, 2024 | June 20, 2024 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Black Diamond Therapeutics, Inc.
Report date June 26, 2026 · Filed June 29, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.71 · Expires 2036-06-25 | Direct | 40,000 |
Reported balance
After 2026-06-26 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-06-26 · Grant · Acquired 40,000 · Balance 40,000 F1: The shares subject to this option shall vest and become exercisable in full upon the earlier to occur of (i) June 26, 2027 or (ii) the Issuer's next annual meeting of stockholders, subject to the Reporting Person's continued service on such vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares subject to this option shall vest and become exercisable in full upon the earlier to occur of (i) June 26, 2027 or (ii) the Issuer's next annual meeting of stockholders, subject to the Reporting Person's continued service on such vesting date.
CRISPR Therapeutics AG
Report date October 13, 2026 · Filed October 15, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common SharesSEC Table I · non-derivative | Direct | 259,736 |
Ending reported balance
After 2026-10-14 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2026-10-13 · Exercise / conversion · Acquired 8,333 · Balance 263,834 F1: Each restricted stock unit represents a contingent right to receive one share of CRSP Common Shares. Row 2 · 2026-10-14 · Sale · Disposed 4,098 · Balance 259,736 F2: Amount reported represents the number of shares required to be sold by the reporting person to cover the tax withholding obligation in connection with the vesting of these restricted stock units. This sale is mandated by the Company's RSU Settlement Policy to fund the tax withholding obligation and does not represent a discretionary trade by the reporting person. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2026-10-13 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2026-10-13 · Exercise / conversion · Disposed 8,333 · Balance 0 F1: Each restricted stock unit represents a contingent right to receive one share of CRSP Common Shares. F3: This restricted stock unit award was granted on October 13, 2023 with respect to 25,000 Common Shares, with (i) one third of the shares vesting on October 13, 2024, (ii) one third of the shares vesting on October 13, 2025, and (iii) one third of the shares vesting on October 13, 2026. |
Filing footnotes · ownership attribution and instrument terms
F1: Each restricted stock unit represents a contingent right to receive one share of CRSP Common Shares.
F2: Amount reported represents the number of shares required to be sold by the reporting person to cover the tax withholding obligation in connection with the vesting of these restricted stock units. This sale is mandated by the Company's RSU Settlement Policy to fund the tax withholding obligation and does not represent a discretionary trade by the reporting person.
F3: This restricted stock unit award was granted on October 13, 2023 with respect to 25,000 Common Shares, with (i) one third of the shares vesting on October 13, 2024, (ii) one third of the shares vesting on October 13, 2025, and (iii) one third of the shares vesting on October 13, 2026.
Oruka Therapeutics, Inc.
Report date June 02, 2026 · Filed June 03, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $55.23 · Expires 2036-06-01 | Direct | 9,136 |
Reported balance
After 2026-06-02 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-06-02 · Grant · Acquired 9,136 · Balance 9,136 F1: The option vests as to 1/12 of the underlying shares monthly from June 2, 2026. |
Filing footnotes · ownership attribution and instrument terms
F1: The option vests as to 1/12 of the underlying shares monthly from June 2, 2026.
Repare Therapeutics Inc.
Report date June 17, 2024 · Filed June 20, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.80 · Expires 2034-06-16 | Direct | 27,200 |
Reported balance
After 2024-06-17 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2024-06-17 · Grant · Acquired 27,200 · Balance 27,200 F1: The option will vest in equal monthly installments over twelve (12) months from the date of grant, subject to Reporting Person continuing to provide service through each such date. |
Filing footnotes · ownership attribution and instrument terms
F1: The option will vest in equal monthly installments over twelve (12) months from the date of grant, subject to Reporting Person continuing to provide service through each such date.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Centessa Pharmaceuticals plc
Report date June 24, 2026 · Filed June 24, 2026
Section 16 reporting ended · disclosed 2026-06-24. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Share Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $5.84 · Expires 2031-02-19 | Direct | 0 |
Reported balance
After 2026-06-24 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-06-24 · Disposition to issuer · Disposed 208,474 · Balance 0 F1: On June 24, 2026, Eli Lilly and Company ("Parent"), through its wholly owned subsidiary LDH XV Corporation ("Purchaser"), acquired all outstanding Ordinary Shares of Centessa Pharmaceuticals plc (the "Company") by means of a scheme of arrangement under Part 26 of the UK Companies Act 2006 (the "Scheme of Arrangement"), pursuant to the Transaction Agreement dated as of March 31, 2026, by and among the Company, Parent and Purchaser (the "Transaction Agreement"). F2: Pursuant to the Transaction Agreement, at the effective time of the Scheme of Arrangement, each outstanding share option, whether or not vested, was automatically cancelled and converted into the right to receive (i) an amount in cash equal to the excess of $38.00 in cash over the per-share exercise price of such option, without interest and less any applicable withholding taxes, and (ii) one non-transferable contingent value right (a "CVR") per underlying Ordinary Share entitling the holders to receive contingent payments of up to an aggregate of $9.00 per Ordinary Share, without interest and less any applicable withholding taxes, contingent upon the achievement of specified milestones set forth in the Contingent Value Rights Agreement between Parent, Purchaser and a rights agent mutually agreeable to the Company and Parent, in each case in accordance with the Transaction Agreement. No share options were exercised prior to the Effective Time. F3: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. |
| Share Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.87 · Expires 2032-06-30 | Direct | 0 |
Reported balance
After 2026-06-24 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-06-24 · Disposition to issuer · Disposed 48,000 · Balance 0 F1: On June 24, 2026, Eli Lilly and Company ("Parent"), through its wholly owned subsidiary LDH XV Corporation ("Purchaser"), acquired all outstanding Ordinary Shares of Centessa Pharmaceuticals plc (the "Company") by means of a scheme of arrangement under Part 26 of the UK Companies Act 2006 (the "Scheme of Arrangement"), pursuant to the Transaction Agreement dated as of March 31, 2026, by and among the Company, Parent and Purchaser (the "Transaction Agreement"). F2: Pursuant to the Transaction Agreement, at the effective time of the Scheme of Arrangement, each outstanding share option, whether or not vested, was automatically cancelled and converted into the right to receive (i) an amount in cash equal to the excess of $38.00 in cash over the per-share exercise price of such option, without interest and less any applicable withholding taxes, and (ii) one non-transferable contingent value right (a "CVR") per underlying Ordinary Share entitling the holders to receive contingent payments of up to an aggregate of $9.00 per Ordinary Share, without interest and less any applicable withholding taxes, contingent upon the achievement of specified milestones set forth in the Contingent Value Rights Agreement between Parent, Purchaser and a rights agent mutually agreeable to the Company and Parent, in each case in accordance with the Transaction Agreement. No share options were exercised prior to the Effective Time. F3: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. |
| Share Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $6.35 · Expires 2033-06-22 | Direct | 0 |
Reported balance
After 2026-06-24 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2026-06-24 · Disposition to issuer · Disposed 48,000 · Balance 0 F1: On June 24, 2026, Eli Lilly and Company ("Parent"), through its wholly owned subsidiary LDH XV Corporation ("Purchaser"), acquired all outstanding Ordinary Shares of Centessa Pharmaceuticals plc (the "Company") by means of a scheme of arrangement under Part 26 of the UK Companies Act 2006 (the "Scheme of Arrangement"), pursuant to the Transaction Agreement dated as of March 31, 2026, by and among the Company, Parent and Purchaser (the "Transaction Agreement"). F2: Pursuant to the Transaction Agreement, at the effective time of the Scheme of Arrangement, each outstanding share option, whether or not vested, was automatically cancelled and converted into the right to receive (i) an amount in cash equal to the excess of $38.00 in cash over the per-share exercise price of such option, without interest and less any applicable withholding taxes, and (ii) one non-transferable contingent value right (a "CVR") per underlying Ordinary Share entitling the holders to receive contingent payments of up to an aggregate of $9.00 per Ordinary Share, without interest and less any applicable withholding taxes, contingent upon the achievement of specified milestones set forth in the Contingent Value Rights Agreement between Parent, Purchaser and a rights agent mutually agreeable to the Company and Parent, in each case in accordance with the Transaction Agreement. No share options were exercised prior to the Effective Time. F3: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. |
| Share Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $8.89 · Expires 2034-06-25 | Direct | 0 |
Reported balance
After 2026-06-24 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2026-06-24 · Disposition to issuer · Disposed 48,000 · Balance 0 F1: On June 24, 2026, Eli Lilly and Company ("Parent"), through its wholly owned subsidiary LDH XV Corporation ("Purchaser"), acquired all outstanding Ordinary Shares of Centessa Pharmaceuticals plc (the "Company") by means of a scheme of arrangement under Part 26 of the UK Companies Act 2006 (the "Scheme of Arrangement"), pursuant to the Transaction Agreement dated as of March 31, 2026, by and among the Company, Parent and Purchaser (the "Transaction Agreement"). F2: Pursuant to the Transaction Agreement, at the effective time of the Scheme of Arrangement, each outstanding share option, whether or not vested, was automatically cancelled and converted into the right to receive (i) an amount in cash equal to the excess of $38.00 in cash over the per-share exercise price of such option, without interest and less any applicable withholding taxes, and (ii) one non-transferable contingent value right (a "CVR") per underlying Ordinary Share entitling the holders to receive contingent payments of up to an aggregate of $9.00 per Ordinary Share, without interest and less any applicable withholding taxes, contingent upon the achievement of specified milestones set forth in the Contingent Value Rights Agreement between Parent, Purchaser and a rights agent mutually agreeable to the Company and Parent, in each case in accordance with the Transaction Agreement. No share options were exercised prior to the Effective Time. F3: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. |
| Share Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $12.43 · Expires 2035-06-20 | Direct | 0 |
Reported balance
After 2026-06-24 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2026-06-24 · Disposition to issuer · Disposed 40,000 · Balance 0 F1: On June 24, 2026, Eli Lilly and Company ("Parent"), through its wholly owned subsidiary LDH XV Corporation ("Purchaser"), acquired all outstanding Ordinary Shares of Centessa Pharmaceuticals plc (the "Company") by means of a scheme of arrangement under Part 26 of the UK Companies Act 2006 (the "Scheme of Arrangement"), pursuant to the Transaction Agreement dated as of March 31, 2026, by and among the Company, Parent and Purchaser (the "Transaction Agreement"). F2: Pursuant to the Transaction Agreement, at the effective time of the Scheme of Arrangement, each outstanding share option, whether or not vested, was automatically cancelled and converted into the right to receive (i) an amount in cash equal to the excess of $38.00 in cash over the per-share exercise price of such option, without interest and less any applicable withholding taxes, and (ii) one non-transferable contingent value right (a "CVR") per underlying Ordinary Share entitling the holders to receive contingent payments of up to an aggregate of $9.00 per Ordinary Share, without interest and less any applicable withholding taxes, contingent upon the achievement of specified milestones set forth in the Contingent Value Rights Agreement between Parent, Purchaser and a rights agent mutually agreeable to the Company and Parent, in each case in accordance with the Transaction Agreement. No share options were exercised prior to the Effective Time. F3: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. |
Filing footnotes · ownership attribution and instrument terms
F1: On June 24, 2026, Eli Lilly and Company ("Parent"), through its wholly owned subsidiary LDH XV Corporation ("Purchaser"), acquired all outstanding Ordinary Shares of Centessa Pharmaceuticals plc (the "Company") by means of a scheme of arrangement under Part 26 of the UK Companies Act 2006 (the "Scheme of Arrangement"), pursuant to the Transaction Agreement dated as of March 31, 2026, by and among the Company, Parent and Purchaser (the "Transaction Agreement").
F2: Pursuant to the Transaction Agreement, at the effective time of the Scheme of Arrangement, each outstanding share option, whether or not vested, was automatically cancelled and converted into the right to receive (i) an amount in cash equal to the excess of $38.00 in cash over the per-share exercise price of such option, without interest and less any applicable withholding taxes, and (ii) one non-transferable contingent value right (a "CVR") per underlying Ordinary Share entitling the holders to receive contingent payments of up to an aggregate of $9.00 per Ordinary Share, without interest and less any applicable withholding taxes, contingent upon the achievement of specified milestones set forth in the Contingent Value Rights Agreement between Parent, Purchaser and a rights agent mutually agreeable to the Company and Parent, in each case in accordance with the Transaction Agreement. No share options were exercised prior to the Effective Time.
F3: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| January 16, 2024 Filed Jan 18, 2024 22:45 UTC | CRISPR Therapeutics AG CRSP · Entity 3852 | Exercise / conversionStock Option (Right to Buy) · Derivative | 20,000 | $0.00 Strike: $19.12 | $0.00 |
DisclosureSEC source: 0000950170-24-005492 · ownership.xml · derivative · entry 4 Kulkarni Samarth · CIK 0001682019 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 59,582 Underlying: Common Shares · 20,000 shares Expires 2027-12-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: This option was granted on December 1, 2017 with respect to 260,000 Common Shares with 100% of the shares vesting in 48 equal monthly installments beginning January 1, 2018. Read SEC document |
| January 16, 2024 Filed Jan 18, 2024 22:45 UTC | CRISPR Therapeutics AG CRSP · Entity 3852 | SaleCommon Shares | 20,000 | $62.50 | $1,250,058.00 |
DisclosureSEC source: 0000950170-24-005492 · ownership.xml · nonDerivative · entry 2 Kulkarni Samarth · CIK 0001682019 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 187,377 F2 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 15, 2023. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $62.2250 to $63.195, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| January 16, 2024 Filed Jan 18, 2024 22:45 UTC | CRISPR Therapeutics AG CRSP · Entity 3852 | Exercise / conversionCommon Shares | 20,000 | $19.12 | $382,400.00 |
DisclosureSEC source: 0000950170-24-005492 · ownership.xml · nonDerivative · entry 1 Kulkarni Samarth · CIK 0001682019 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 207,377 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: 200,000 common shares were recently transferred to The Kulkarni 2023 GRAT. Read SEC document |
| October 13, 2023 Filed Oct 17, 2023 21:51 UTC | CRISPR Therapeutics AG CRSP · Entity 3852 | GrantRestricted Stock Unit · Derivative | 25,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-23-053818 · ownership.xml · derivative · entry 2 Kulkarni Samarth · CIK 0001682019 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Shares · 25,000 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of CRSP Common Shares. F3 · derivative.exercise_date: This restricted stock unit award was granted on October 13, 2023 with respect to 25,000 Common Shares, with (i) one third of the shares vesting on October 13, 2024, (ii) one third of the shares vesting on October 13, 2025, and (iii) one third of the shares vesting on October 13, 2026. F3 · derivative.expiration_date: This restricted stock unit award was granted on October 13, 2023 with respect to 25,000 Common Shares, with (i) one third of the shares vesting on October 13, 2024, (ii) one third of the shares vesting on October 13, 2025, and (iii) one third of the shares vesting on October 13, 2026. Read SEC document |
| October 13, 2023 Filed Oct 17, 2023 21:51 UTC | CRISPR Therapeutics AG CRSP · Entity 3852 | GrantStock Option (Right to Buy) · Derivative | 52,500 | $0.00 Strike: $44.31 | $0.00 |
DisclosureSEC source: 0000950170-23-053818 · ownership.xml · derivative · entry 1 Kulkarni Samarth · CIK 0001682019 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 52,500 Underlying: Common Shares · 52,500 shares Expires 2033-10-13 F1 · derivative.exercise_date: This option was granted on October 13, 2023 with respect to 52,500 Common Shares. 100% of the shares will vest in 48 equal monthly installments, with the first vesting date of November 13, 2023. Read SEC document |
| June 22, 2023 Filed Jun 23, 2023 21:07 UTC | Centessa Pharmaceuticals plc CNTA · Entity 35581 | GrantShare Option (right to buy) · Derivative | 48,000 | $0.00 Strike: $6.35 | $0.00 |
DisclosureSEC source: 0001847903-23-000130 · wf-form4_168755444876417.xml · derivative · entry 1 Kulkarni Samarth · CIK 0001682019 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 48,000 Underlying: Ordinary Shares · 48,000 shares Expires 2033-06-22 F1 · derivative.exercise_date: The shares subject to such option will vest in full on the earlier of (i) the first anniversary of the grant date or (ii) the Issuer's next annual meeting of shareholders, subject to continued service as a director through the applicable vesting date. F2 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. Read SEC document |
| June 08, 2023 Filed Jun 12, 2023 20:25 UTC | Repare Therapeutics Inc. RPTX · Entity 68433 | GrantStock Option (right to buy) · Derivative | 27,200 | $0.00 Strike: $11.66 | $0.00 |
DisclosureSEC source: 0001209191-23-036308 · doc4.xml · derivative · entry 1 Kulkarni Samarth · CIK 0001682019 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 27,200 Underlying: Common Shares · 27,200 shares Expires 2033-06-07 F1 · derivative.exercise_date: The option will vest in equal monthly installments over twelve (12) months from the date of grant, subject to Reporting Person continuing to provide service through each such date. Read SEC document |
| May 30, 2023 Filed Jun 1, 2023 21:44 UTC | CRISPR Therapeutics AG CRSP · Entity 3852 | Exercise / conversionStock Option (Right to Buy) · Derivative | 25,000 | $0.00 Strike: $19.12 | $0.00 |
DisclosureSEC source: 0001209191-23-033394 · doc4.xml · derivative · entry 6 Kulkarni Samarth · CIK 0001682019 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 79,582 Underlying: Common Shares · 25,000 shares Expires 2027-12-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · derivative.exercise_date: This option was granted on December 1, 2017 with respect to 260,000 Common Shares with 100% of the shares vesting in 48 equal monthly installments beginning January 1, 2018. Read SEC document |
| May 30, 2023 Filed Jun 1, 2023 21:44 UTC | CRISPR Therapeutics AG CRSP · Entity 3852 | SaleCommon Shares | 2,400 | $66.83 | $160,401.12 |
DisclosureSEC source: 0001209191-23-033394 · doc4.xml · nonDerivative · entry 5 Kulkarni Samarth · CIK 0001682019 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 387,377 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 26, 2022. F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $66.15 to $66.76, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| May 30, 2023 Filed Jun 1, 2023 21:44 UTC | CRISPR Therapeutics AG CRSP · Entity 3852 | SaleCommon Shares | 9,300 | $65.63 | $610,359.00 |
DisclosureSEC source: 0001209191-23-033394 · doc4.xml · nonDerivative · entry 4 Kulkarni Samarth · CIK 0001682019 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 389,777 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 26, 2022. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $64.97 to $65.91, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| May 30, 2023 Filed Jun 1, 2023 21:44 UTC | CRISPR Therapeutics AG CRSP · Entity 3852 | SaleCommon Shares | 5,999 | $64.46 | $386,681.74 |
DisclosureSEC source: 0001209191-23-033394 · doc4.xml · nonDerivative · entry 3 Kulkarni Samarth · CIK 0001682019 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 399,077 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 26, 2022. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $63.97 to $64.89, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| May 30, 2023 Filed Jun 1, 2023 21:44 UTC | CRISPR Therapeutics AG CRSP · Entity 3852 | SaleCommon Shares | 7,301 | $63.61 | $464,452.38 |
DisclosureSEC source: 0001209191-23-033394 · doc4.xml · nonDerivative · entry 2 Kulkarni Samarth · CIK 0001682019 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 405,076 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 26, 2022. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $62.96 to $63.93, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| May 30, 2023 Filed Jun 1, 2023 21:44 UTC | CRISPR Therapeutics AG CRSP · Entity 3852 | Exercise / conversionCommon Shares | 25,000 | $19.12 | $478,000.00 |
DisclosureSEC source: 0001209191-23-033394 · doc4.xml · nonDerivative · entry 1 Kulkarni Samarth · CIK 0001682019 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 412,377 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 16, 2023 Filed May 18, 2023 01:08 UTC | Black Diamond Therapeutics, Inc. BDTX · Entity 6669 | GrantStock Option (Right to Buy) · Derivative | 16,500 | $0.00 Strike: $1.82 | $0.00 |
DisclosureSEC source: 0001415889-23-008243 · form4-05182023_010501.xml · derivative · entry 1 Kulkarni Samarth · CIK 0001682019 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 16,500 Underlying: Common Stock · 16,500 shares Expires 2033-05-15 F1 · derivative.exercise_date: The shares subject to this option shall vest and become exercisable in full upon the earlier to occur of (i) May 16, 2024 or (ii) the Issuer's next annual meeting of stockholders, subject to the Reporting Person's continued service on such vesting date. Read SEC document |
| April 25, 2023 Filed Apr 27, 2023 21:37 UTC | CRISPR Therapeutics AG CRSP · Entity 3852 | Exercise / conversionStock Option (Right to Buy) · Derivative | 25,000 | $0.00 Strike: $19.12 | $0.00 |
DisclosureSEC source: 0001209191-23-025901 · doc4.xml · derivative · entry 4 Kulkarni Samarth · CIK 0001682019 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 104,582 Underlying: Common Shares · 25,000 shares Expires 2027-12-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: This option was granted on December 1, 2017 with respect to 260,000 Common Shares with 100% of the shares vesting in 48 equal monthly installments beginning January 1, 2018. Read SEC document |
| April 25, 2023 Filed Apr 27, 2023 21:37 UTC | CRISPR Therapeutics AG CRSP · Entity 3852 | SaleCommon Shares | 4,393 | $51.45 | $226,021.17 |
DisclosureSEC source: 0001209191-23-025901 · doc4.xml · nonDerivative · entry 3 Kulkarni Samarth · CIK 0001682019 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 387,377 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 26, 2022. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $51.17 to $51.67, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| April 25, 2023 Filed Apr 27, 2023 21:37 UTC | CRISPR Therapeutics AG CRSP · Entity 3852 | SaleCommon Shares | 20,607 | $50.50 | $1,040,616.41 |
DisclosureSEC source: 0001209191-23-025901 · doc4.xml · nonDerivative · entry 2 Kulkarni Samarth · CIK 0001682019 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 391,770 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 26, 2022. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $50.17 to $51.165, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| April 25, 2023 Filed Apr 27, 2023 21:37 UTC | CRISPR Therapeutics AG CRSP · Entity 3852 | Exercise / conversionCommon Shares | 25,000 | $19.12 | $478,000.00 |
DisclosureSEC source: 0001209191-23-025901 · doc4.xml · nonDerivative · entry 1 Kulkarni Samarth · CIK 0001682019 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 412,377 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 29, 2023 Filed Mar 31, 2023 21:49 UTC | CRISPR Therapeutics AG CRSP · Entity 3852 | Exercise / conversionStock Option (Right to Buy) · Derivative | 25,000 | $0.00 Strike: $19.12 | $0.00 |
DisclosureSEC source: 0001209191-23-021911 · doc4.xml · derivative · entry 4 Kulkarni Samarth · CIK 0001682019 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 129,582 Underlying: Common Shares · 25,000 shares Expires 2027-12-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: This option was granted on December 1, 2017 with respect to 260,000 Common Shares with 100% of the shares vesting in 48 equal monthly installments beginning January 1, 2018. Read SEC document |
| March 29, 2023 Filed Mar 31, 2023 21:49 UTC | CRISPR Therapeutics AG CRSP · Entity 3852 | SaleCommon Shares | 5,281 | $44.78 | $236,506.42 |
DisclosureSEC source: 0001209191-23-021911 · doc4.xml · nonDerivative · entry 3 Kulkarni Samarth · CIK 0001682019 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 387,377 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $44.63 to $44.97, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| March 29, 2023 Filed Mar 31, 2023 21:49 UTC | CRISPR Therapeutics AG CRSP · Entity 3852 | SaleCommon Shares | 19,719 | $44.37 | $874,997.10 |
DisclosureSEC source: 0001209191-23-021911 · doc4.xml · nonDerivative · entry 2 Kulkarni Samarth · CIK 0001682019 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 392,658 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $43.63 to $44.62, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| March 29, 2023 Filed Mar 31, 2023 21:49 UTC | CRISPR Therapeutics AG CRSP · Entity 3852 | Exercise / conversionCommon Shares | 25,000 | $19.12 | $478,000.00 |
DisclosureSEC source: 0001209191-23-021911 · doc4.xml · nonDerivative · entry 1 Kulkarni Samarth · CIK 0001682019 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 412,377 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 13, 2023 Filed Mar 14, 2023 21:47 UTC | CRISPR Therapeutics AG CRSP · Entity 3852 | Tax withholdingCommon Shares | 4,086 | $43.22 | $176,596.92 |
DisclosureSEC source: 0001209191-23-018566 · doc4.xml · nonDerivative · entry 4 Kulkarni Samarth · CIK 0001682019 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 387,377 F2 · shares: Amount reported represents the number of shares required to be sold by the reporting person to cover the tax withholding obligation in connection with the vesting of these restricted stock units. This sale is mandated by the Company's RSU Settlement Policy to fund the tax withholding obligation and does not represent a discretionary trade by the reporting person. Read SEC document |
| March 13, 2023 Filed Mar 14, 2023 21:47 UTC | CRISPR Therapeutics AG CRSP · Entity 3852 | Tax withholdingCommon Shares | 5,358 | $43.22 | $231,572.76 |
DisclosureSEC source: 0001209191-23-018566 · doc4.xml · nonDerivative · entry 2 Kulkarni Samarth · CIK 0001682019 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 382,463 F2 · shares: Amount reported represents the number of shares required to be sold by the reporting person to cover the tax withholding obligation in connection with the vesting of these restricted stock units. This sale is mandated by the Company's RSU Settlement Policy to fund the tax withholding obligation and does not represent a discretionary trade by the reporting person. Read SEC document |
| March 11, 2023 Filed Mar 14, 2023 21:47 UTC | CRISPR Therapeutics AG CRSP · Entity 3852 | Exercise / conversionRestricted Stock Units · Derivative | 9,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-23-018566 · doc4.xml · derivative · entry 8 Kulkarni Samarth · CIK 0001682019 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,000 Underlying: Common Shares · 9,000 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of CRSP Common Shares. F1 · price: Each restricted stock unit represents a contingent right to receive one share of CRSP Common Shares. F6 · derivative.exercise_date: This restricted stock unit award was granted on March 11, 2021 with respect to 36,000 Common Shares, with (i) one quarter of the shares vesting on March 11, 2022, (ii) one quarter of the shares vesting on March 11, 2023, (iii) one quarter of the shares vesting on March 11, 2024, and (iv) one quarter of the shares vesting on March 11, 2025. F6 · derivative.expiration_date: This restricted stock unit award was granted on March 11, 2021 with respect to 36,000 Common Shares, with (i) one quarter of the shares vesting on March 11, 2022, (ii) one quarter of the shares vesting on March 11, 2023, (iii) one quarter of the shares vesting on March 11, 2024, and (iv) one quarter of the shares vesting on March 11, 2025. Read SEC document |
| March 11, 2023 Filed Mar 14, 2023 21:47 UTC | CRISPR Therapeutics AG CRSP · Entity 3852 | Exercise / conversionCommon Shares | 9,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-23-018566 · doc4.xml · nonDerivative · entry 3 Kulkarni Samarth · CIK 0001682019 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 391,463 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of CRSP Common Shares. Read SEC document |
| March 10, 2023 Filed Mar 14, 2023 21:47 UTC | CRISPR Therapeutics AG CRSP · Entity 3852 | GrantRestricted Stock Units · Derivative | 77,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-018566 · doc4.xml · derivative · entry 7 Kulkarni Samarth · CIK 0001682019 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 77,000 Underlying: Common Shares · 77,000 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of CRSP Common Shares. F5 · derivative.exercise_date: This restricted stock unit award was granted on March 10, 2023 with respect to 77,000 Common Shares, with (i) one quarter of the shares vesting on March 10, 2024, (ii) one quarter of the shares vesting on March 10, 2025, (iii) one quarter of the shares vesting on March 10, 2026, and (iv) one quarter of the shares vesting on March 10, 2027. F5 · derivative.expiration_date: This restricted stock unit award was granted on March 10, 2023 with respect to 77,000 Common Shares, with (i) one quarter of the shares vesting on March 10, 2024, (ii) one quarter of the shares vesting on March 10, 2025, (iii) one quarter of the shares vesting on March 10, 2026, and (iv) one quarter of the shares vesting on March 10, 2027. Read SEC document |
| March 10, 2023 Filed Mar 14, 2023 21:47 UTC | CRISPR Therapeutics AG CRSP · Entity 3852 | GrantStock Option (Right to Buy) · Derivative | 188,000 | $0.00 Strike: $43.22 | $0.00 |
DisclosureSEC source: 0001209191-23-018566 · doc4.xml · derivative · entry 6 Kulkarni Samarth · CIK 0001682019 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 188,000 Underlying: Common Shares · 188,000 shares Expires 2033-03-10 F4 · derivative.exercise_date: This option was granted on March 10, 2023 with respect to 188,000 Common Shares. 100% of the shares will vest in 48 equal monthly installments, with the first vesting date of April 10, 2023. Read SEC document |
| March 10, 2023 Filed Mar 14, 2023 21:47 UTC | CRISPR Therapeutics AG CRSP · Entity 3852 | Exercise / conversionRestricted Stock Units · Derivative | 11,833 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-23-018566 · doc4.xml · derivative · entry 5 Kulkarni Samarth · CIK 0001682019 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Shares · 11,833 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of CRSP Common Shares. F1 · price: Each restricted stock unit represents a contingent right to receive one share of CRSP Common Shares. F3 · derivative.exercise_date: This restricted stock unit award was granted on March 10, 2020 with respect to 35,500 Common Shares, with (i) one third of the shares vesting on March 10, 2021, (ii) one third of the shares vesting on March 10, 2022, and (iii) one third of the shares vesting on March 10, 2023. F3 · derivative.expiration_date: This restricted stock unit award was granted on March 10, 2020 with respect to 35,500 Common Shares, with (i) one third of the shares vesting on March 10, 2021, (ii) one third of the shares vesting on March 10, 2022, and (iii) one third of the shares vesting on March 10, 2023. Read SEC document |
| March 10, 2023 Filed Mar 14, 2023 21:47 UTC | CRISPR Therapeutics AG CRSP · Entity 3852 | Exercise / conversionCommon Shares | 11,833 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-23-018566 · doc4.xml · nonDerivative · entry 1 Kulkarni Samarth · CIK 0001682019 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 387,821 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of CRSP Common Shares. Read SEC document |
| February 27, 2023 Filed Mar 1, 2023 23:11 UTC | CRISPR Therapeutics AG CRSP · Entity 3852 | Exercise / conversionStock Option (Right to Buy) · Derivative | 25,000 | $0.00 Strike: $19.12 | $0.00 |
DisclosureSEC source: 0001209191-23-014273 · doc4.xml · derivative · entry 5 Kulkarni Samarth · CIK 0001682019 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 154,582 Underlying: Common Shares · 25,000 shares Expires 2027-12-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: This option was granted on December 1, 2017 with respect to 260,000 Common Shares with 100% of the shares vesting in 48 equal monthly installments beginning January 1, 2018. Read SEC document |
| February 27, 2023 Filed Mar 1, 2023 23:11 UTC | CRISPR Therapeutics AG CRSP · Entity 3852 | SaleCommon Shares | 1,100 | $49.20 | $54,118.46 |
DisclosureSEC source: 0001209191-23-014273 · doc4.xml · nonDerivative · entry 4 Kulkarni Samarth · CIK 0001682019 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 375,988 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $49.1350 to $49.24, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| February 27, 2023 Filed Mar 1, 2023 23:11 UTC | CRISPR Therapeutics AG CRSP · Entity 3852 | SaleCommon Shares | 13,720 | $48.57 | $666,414.70 |
DisclosureSEC source: 0001209191-23-014273 · doc4.xml · nonDerivative · entry 3 Kulkarni Samarth · CIK 0001682019 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 377,088 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $48.13 to $49.11, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| February 27, 2023 Filed Mar 1, 2023 23:11 UTC | CRISPR Therapeutics AG CRSP · Entity 3852 | SaleCommon Shares | 10,180 | $47.71 | $485,710.20 |
DisclosureSEC source: 0001209191-23-014273 · doc4.xml · nonDerivative · entry 2 Kulkarni Samarth · CIK 0001682019 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 390,808 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $47.13 to $48.07, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| February 27, 2023 Filed Mar 1, 2023 23:11 UTC | CRISPR Therapeutics AG CRSP · Entity 3852 | Exercise / conversionCommon Shares | 25,000 | $19.12 | $478,000.00 |
DisclosureSEC source: 0001209191-23-014273 · doc4.xml · nonDerivative · entry 1 Kulkarni Samarth · CIK 0001682019 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 400,988 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 21, 2023 Filed Feb 22, 2023 22:38 UTC | CRISPR Therapeutics AG CRSP · Entity 3852 | Tax withholdingCommon Shares | 6,373 | $48.26 | $307,560.98 |
DisclosureSEC source: 0001209191-23-011782 · doc4.xml · nonDerivative · entry 2 Kulkarni Samarth · CIK 0001682019 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 375,988 F2 · shares: Amount reported represents the number of shares required to be sold by the reporting person to cover the tax withholding obligation in connection with the vesting of these restricted stock units. This sale is mandated by the Company's RSU Settlement Policy to fund the tax withholding obligation and does not represent a discretionary trade by the reporting person. Read SEC document |
| February 18, 2023 Filed Feb 22, 2023 22:38 UTC | CRISPR Therapeutics AG CRSP · Entity 3852 | Exercise / conversionRestricted Stock Units · Derivative | 13,250 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-23-011782 · doc4.xml · derivative · entry 3 Kulkarni Samarth · CIK 0001682019 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 39,750 Underlying: Common Shares · 13,250 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of CRSP Common Shares. F1 · price: Each restricted stock unit represents a contingent right to receive one share of CRSP Common Shares. F3 · derivative.exercise_date: This restricted stock unit award was granted on February 18, 2022 with respect to 53,000 Common Shares, with (i) one quarter of the shares vesting on February 18, 2023, (ii) one quarter of the shares vesting on February 18, 2024, (iii) one quarter of the shares vesting on February 18, 2025, and (iv) one quarter of the shares vesting on February 18, 2026. F3 · derivative.expiration_date: This restricted stock unit award was granted on February 18, 2022 with respect to 53,000 Common Shares, with (i) one quarter of the shares vesting on February 18, 2023, (ii) one quarter of the shares vesting on February 18, 2024, (iii) one quarter of the shares vesting on February 18, 2025, and (iv) one quarter of the shares vesting on February 18, 2026. Read SEC document |
| February 18, 2023 Filed Feb 22, 2023 22:38 UTC | CRISPR Therapeutics AG CRSP · Entity 3852 | Exercise / conversionCommon Shares | 13,250 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-23-011782 · doc4.xml · nonDerivative · entry 1 Kulkarni Samarth · CIK 0001682019 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 382,361 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of CRSP Common Shares. Read SEC document |
| January 27, 2023 Filed Jan 31, 2023 22:34 UTC | CRISPR Therapeutics AG CRSP · Entity 3852 | Exercise / conversionStock Option (Right to Buy) · Derivative | 25,000 | $0.00 Strike: $19.12 | $0.00 |
DisclosureSEC source: 0001209191-23-005769 · doc4.xml · derivative · entry 4 Kulkarni Samarth · CIK 0001682019 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 179,582 Underlying: Common Shares · 25,000 shares Expires 2027-12-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: This option was granted on December 1, 2017 with respect to 260,000 Common Shares with 100% of the shares vesting in 48 equal monthly installments beginning January 1, 2018. Read SEC document |
| January 27, 2023 Filed Jan 31, 2023 22:34 UTC | CRISPR Therapeutics AG CRSP · Entity 3852 | SaleCommon Shares | 23,200 | $51.54 | $1,195,711.76 |
DisclosureSEC source: 0001209191-23-005769 · doc4.xml · nonDerivative · entry 3 Kulkarni Samarth · CIK 0001682019 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 369,111 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $51.02 to $51.92, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| January 27, 2023 Filed Jan 31, 2023 22:34 UTC | CRISPR Therapeutics AG CRSP · Entity 3852 | SaleCommon Shares | 1,800 | $50.60 | $91,085.76 |
DisclosureSEC source: 0001209191-23-005769 · doc4.xml · nonDerivative · entry 2 Kulkarni Samarth · CIK 0001682019 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 392,311 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $50.02 to $50.99, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| January 27, 2023 Filed Jan 31, 2023 22:34 UTC | CRISPR Therapeutics AG CRSP · Entity 3852 | Exercise / conversionCommon Shares | 25,000 | $19.12 | $478,000.00 |
DisclosureSEC source: 0001209191-23-005769 · doc4.xml · nonDerivative · entry 1 Kulkarni Samarth · CIK 0001682019 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 394,111 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 28, 2022 Filed Dec 30, 2022 22:33 UTC | CRISPR Therapeutics AG CRSP · Entity 3852 | Exercise / conversionStock Option (Right to Buy) · Derivative | 25,000 | $0.00 Strike: $19.12 | $0.00 |
DisclosureSEC source: 0001209191-22-063026 · doc4.xml · derivative · entry 4 Kulkarni Samarth · CIK 0001682019 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 204,582 Underlying: Common Shares · 25,000 shares Expires 2027-12-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: This option was granted on December 1, 2017 with respect to 260,000 Common Shares with 100% of the shares vesting in 48 equal monthly installments beginning January 1, 2018. Read SEC document |
| December 28, 2022 Filed Dec 30, 2022 22:33 UTC | CRISPR Therapeutics AG CRSP · Entity 3852 | SaleCommon Shares | 4,634 | $41.45 | $192,100.62 |
DisclosureSEC source: 0001209191-22-063026 · doc4.xml · nonDerivative · entry 3 Kulkarni Samarth · CIK 0001682019 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 369,111 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $41.23 to $41.87, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| December 28, 2022 Filed Dec 30, 2022 22:33 UTC | CRISPR Therapeutics AG CRSP · Entity 3852 | SaleCommon Shares | 20,366 | $40.81 | $831,189.41 |
DisclosureSEC source: 0001209191-22-063026 · doc4.xml · nonDerivative · entry 2 Kulkarni Samarth · CIK 0001682019 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 373,745 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $40.22 to $41.20, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| December 28, 2022 Filed Dec 30, 2022 22:33 UTC | CRISPR Therapeutics AG CRSP · Entity 3852 | Exercise / conversionCommon Shares | 25,000 | $19.12 | $478,000.00 |
DisclosureSEC source: 0001209191-22-063026 · doc4.xml · nonDerivative · entry 1 Kulkarni Samarth · CIK 0001682019 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 394,111 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 06, 2022 Filed Dec 8, 2022 22:35 UTC | CRISPR Therapeutics AG CRSP · Entity 3852 | Exercise / conversionStock Option (Right to Buy) · Derivative | 58,233 | $0.00 Strike: $1.81 | $0.00 |
DisclosureSEC source: 0001209191-22-060387 · doc4.xml · derivative · entry 2 Kulkarni Samarth · CIK 0001682019 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Shares · 58,233 shares Expires 2025-09-10 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: This option was granted on September 10, 2015 with respect to 321,712 Common Shares with 120,640 of the shares vested on August 1, 2016, the first anniversary of employment commencement, and the remainder vested in equal 36 monthly installments thereafter. Read SEC document |
| December 06, 2022 Filed Dec 8, 2022 22:35 UTC | CRISPR Therapeutics AG CRSP · Entity 3852 | Exercise / conversionCommon Shares | 58,233 | $1.81 | $105,401.73 |
DisclosureSEC source: 0001209191-22-060387 · doc4.xml · nonDerivative · entry 1 Kulkarni Samarth · CIK 0001682019 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 369,111 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 05, 2022 Filed Dec 6, 2022 22:49 UTC | CRISPR Therapeutics AG CRSP · Entity 3852 | Tax withholdingCommon Shares | 19,401 | $52.26 | $1,013,896.26 |
DisclosureSEC source: 0001209191-22-060093 · doc4.xml · nonDerivative · entry 2 Kulkarni Samarth · CIK 0001682019 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 310,878 F3 · kind: On December 3, 2019, the reporting person was granted 120,000 restricted stock units. On December 3, 2022, 40,000 restricted stock units vested. Amount reported represents the number of shares required to be sold by the reporting person to cover the tax withholding obligation in connection with the vesting of these restricted stock units. This sale is mandated by the Company's RSU Settlement Policy to fund the tax withholding obligation and does not represent a discretionary trade by the reporting person. Read SEC document |
| December 03, 2022 Filed Dec 6, 2022 22:49 UTC | CRISPR Therapeutics AG CRSP · Entity 3852 | Exercise / conversionRestricted Stock Units · Derivative | 40,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-22-060093 · doc4.xml · derivative · entry 3 Kulkarni Samarth · CIK 0001682019 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Shares · 40,000 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of CRSP Common Shares. F2 · price: Each restricted stock unit represents a contingent right to receive one share of CRSP Common Shares. F1 · derivative.exercise_date: The restricted stock units shall vest as follows: two-thirds of the grant shall vest on December 3, 2021 and the remaining one-third shall vest on December 3, 2022. F1 · derivative.expiration_date: The restricted stock units shall vest as follows: two-thirds of the grant shall vest on December 3, 2021 and the remaining one-third shall vest on December 3, 2022. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.